Option chain shows key data for Enfusion's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Enfusion.

Enfusion (NYSE:ENFN) Stock, Option Chain

Enfusion

Enfusion Inc is a software-as-a-service (SaaS) provider focused on transforming the investment management industry. Its solutions are designed to eliminate technology and information barriers, empowering investment managers to make and execute an informed investment decisions in real-time. It simplifies investment and operational workflows by unifying mission-critical systems and coalescing data into a single dataset resulting in a single source of truth. It generates maximum revenue from Americas, followed by Asia Pacific and Europe, Middle East, and Africa.

Earnings

News

Small Cap

Markets

Analyst Ratings

Trading Ideas

ENFN

Enfusion, Inc. (NYSE: ENFN) reported $49.46 million in revenue for the quarter ended June 2024, representing a year-over-year increase of 15.8%. EPS of $0.05 for the same period compares to $0.04 a year ago.

Enfusion Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

2024.Businessman.Shutterstock

Analyst Color

Equities

Downgrades

Price Target

Goldman Sachs downgrades Enfusion from Neutral to Sell, lowers price target from $9 to $8, expects stock to be range-bound in 2024 with slower growth than Street estimates due to company-specific challenges. Analyst will watch for improvements to become more positive on the stock.

Enfusion Stock To Remain Range-Bound In 2024 Amid Stable Hedge Fund Market: Goldman Sachs Analyst Downgrades Stock

Long Ideas

Pre-Market Outlook

TBBK

U.S. stocks closed slightly lower on Friday, but the S&amp;P 500 closed out last year with a gain of 24.2%. The Dow closed the year with a 13.7% gain, while the Nasdaq Composite surged 43.4% to record its best year since 2020.

This Analyst With 84% Accuracy Rate Sees Around 13% Upside In Darden Restaurants - Here Are 5 Stock Picks For 2023 From Wall Street&#39;s Most Accurate Analysts

Enfusion Inc

Editor&#8217;s note: This story has been corrected to state that MicroStrategy&#8217;s dollar cost average price for Bitcoin is below, not above, the current price of the cryptocurrency. 
With Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) prices peaking to all-time high levels, MicroStrategy's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) aggressive Bitcoin accumulation strategy has once again become a focal point in discussions among <a href="https://www.benzinga.com/markets/equities/24/12/42503221/microstrategy-shares-surge-nearly-7-amid-nasdaq-100-inclusion-and-bitcoins-new-record-high">traders and analysts</a>.
What Happened: In a tweet on Monday, industry expert Alex Kolicich addressed common misconceptions about MSTR in a recent tweet, explaining that the stock is neither a leveraged nor a synthetic call option on Bitcoin. 
Instead, Kolicich pointed out several structural inefficiencies:
<ul>
<li>MSTR trades at a 140% premium to its Bitcoin holdings&#8217; net asset value (NAV).</li>
<li>Each $1 invested in MSTR stock provides only $0.45 of Bitcoin exposure, far less than direct Bitcoin ownership.</li>
</ul>
Kolicich further <a href="https://x.com/AlexKolicich/status/1868705490387321177">elaborated</a> that MicroStrategy is not leveraged but instead deleveraged, offering reduced Bitcoin exposure compared to direct investments. 
He highlighted alternatives like BITX, which provide 2x leverage without a NAV premium.
Additionally, while traditional call options on assets typically offer leveraged upside due to their long volatility exposure, MSTR's convertible bonds effectively short volatility, diluting shareholder returns as Bitcoin prices rise.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42509614/microstrategy-expands-bitcoin-holdings-by-15350-btc-worth-15-billion-after-joining-nasdaq-100">MicroStrategy Expands Bitcoin Holdings By 15,350 BTC Worth $1.5 Billion After Joining Nasdaq 100</a>
Why It Matters: Crypto trader TheFlowHorse on Dec. 17 in a post on X emphasized the implications of Saylor&#8217;s aggressive Bitcoin purchases, noting that these acquisitions have significantly raised MicroStrategy's DCA to $61,000. 
This figure is approximately 40% lower than Bitcoin's current price, introducing potential risks if prices fall significantly. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Take a look at Saylor&#39;s recent Bitcoin buys. The buys up here are so large that he has increased his dollar cost average price by nearly 50%, to 61k. That level is around 40% away. We haven&#39;t had a pullback of that magnitude for years, but at some point you have to wonder if in… <a href="https://t.co/erhdvrErn2">pic.twitter.com/erhdvrErn2</a>
&mdash; HORSE (@TheFlowHorse) <a href="https://twitter.com/TheFlowHorse/status/1868763016642052542?ref_src=twsrc%5Etfw">December 16, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Analysts warn that while Bitcoin&#8217;s pullbacks have historically been rare, Saylor's strategy could leave MSTR exposed to potential downside risk, especially with its C-Corp structure subject to double taxation, unlike <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42275232/leveraged-microstrategy-etfs-are-playing-with-fire-experts-warn">more efficient ETFs</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42522606/trump-is-serious-about-creating-a-bitcoin-reserve-says-microstrategys-michael-saylorurges-to-buy-btc-before-it-goes-up-by-100x">Trump Serious About Bitcoin Reserve, Says MicroStrategy&#8217;s Michael Saylor: &#8216;Buy It Now And Own The Future&#8217;</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

MSTR

MicroStrategy's Aggressive Bitcoin Strategy Raises Eyebrows In Crypto Community (CORRECTED)

D.R. Horton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>) has outperformed the market over the past 5 years by 8.87% on an annualized basis producing an average annual return of 21.66%. Currently, D.R. Horton has a market capitalization of $43.76 billion. 
Buying $100 In DHI: If an investor had bought $100 of DHI stock 5 years ago, it would be worth $268.50 today based on a price of $136.25 for DHI at the time of writing.
<h3>D.R. Horton's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734564608_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning D.R. Horton Stock In The Last 5 Years

Offerings

NUKK

Nukkleus Announces Strategic $10.0M Private Placement Priced Above-The-Market Under Nasdaq Rules

On Wednesday, House Republicans rejected Speaker Mike Johnson's proposed spending bill that would have extended federal funding until March 14 and averted a<a href="https://www.benzinga.com/24/12/42544562/congressional-leaders-reach-bipartisan-deal-to-avert-government-shutdown"> government shutdown. </a>&nbsp;
The Details: President-elect Donald Trump and Elon Musk joined a large portion of House GOP members in opposing the compromise bill which included numerous Democratic policy priorities.&nbsp;
Read Next: <a href="https://www.benzinga.com/news/global/24/12/42559347/trump-administration-could-ban-amazons-top-selling-routers-linked-to-chinese-cyberattacks-report">Trump Administration Could Ban Amazon&#8217;s Top-Selling Routers Linked To Chinese Cyberattacks: Report</a>
Some of the Republican-contested late additions from Democrats included a pay raise for members of Congress, new regulations for health plan administrators and federal funds to rebuild the collapsed Francis Scott Key Bridge. The provisions were added after Johnson opened the door with a last-minute addition of&nbsp; $10 billion in aid for farmers.&nbsp;
Trump and Vice President-elect JD Vance blasted the proposed spending bill on Wednesday afternoon in a statement posted on social media.&nbsp;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">A statement from President Donald J. Trump and Vice President-Elect JD Vance: The most foolish and inept thing ever done by Congressional Republicans was allowing our country to hit the debt ceiling in 2025. It was a mistake and is now something that must be addressed.…
&mdash; JD Vance (@JDVance) <a href="https://twitter.com/JDVance/status/1869495076604227726?ref_src=twsrc%5Etfw">December 18, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Musk actively criticized the bill on his social media platform X throughout the day on Wednesday. He also posted victoriously on the platform after the bill was rejected.&nbsp;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Your elected representatives have heard you and now the terrible bill is dead. The voice of the people has triumphed! VOX POPULI VOX DEI
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1869487359420727338?ref_src=twsrc%5Etfw">December 18, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
What's Next: Johnson, a Republican from Louisiana, has not outlined a backup plan and the next step remains unclear, according to sources familiar with the discussions,<a href="https://www.washingtonpost.com/business/2024/12/18/government-shutdown-house-vote-cr/"> per</a> the Washington Post. Most federal operations would shut down at 12:01 a.m. Saturday if Congress does not pass a bill to extend the deadline.  
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/24/12/42564443/santa-came-early-with-rate-cut-but-federal-reserve-brings-coal-next-year-experts-weigh-in-on-rate-cut-feds-2025-projections">&#8216;Santa Came Early&#8217; But Fed Brings &#8216;Coal Next Year&#8217;: Experts Weigh In On Interest Rate Cut, 2025 Projections</a></li>
</ul>
This image was generated using artificial intelligence via Dall-E 3.

Social Media

Politics

Legal

General

House Republicans Reject Spending Bill Under Pressure From Trump, Musk: Government Faces Shutdown

Arista Networks (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>) has outperformed the market over the past 10 years by 27.96% on an annualized basis producing an average annual return of 38.9%. Currently, Arista Networks has a market capitalization of $136.68 billion. 
Buying $1000 In ANET: If an investor had bought $1000 of ANET stock 10 years ago, it would be worth $26,491.80 today based on a price of $108.50 for ANET at the time of writing.
<h3>Arista Networks's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734563707_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANET

Here's How Much You Would Have Made Owning Arista Networks Stock In The Last 10 Years

Entrepreneur and investor Mark Cuban has been an outspoken critic of Elon Musk and the X social media platform. In a recent interview, Cuban shares what sets Bluesky apart from X and why he's spending<a href="https://www.benzinga.com/general/social-media/24/12/42421291/alexandria-ocasio-cortez-aoc-hits-1-million-followers-with-top-bluesky-account-mark-cuban-gains-popularity-jack-dorsey-notably-absent"> more time there.</a>
Why Cuban Loves Bluesky: Alternate platforms to X, formerly known as Twitter, such as Bluesky and Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)-owned Threads have <a href="https://www.benzinga.com/general/social-media/24/12/42305424/threads-takes-on-x-bluesky-with-new-search-options-making-it-easier-for-you">seen a rise</a> in user growth after the 2024 presidential election.
Cuban is spending more time on Bluesky where his 775,000 plus <a href="https://bsky.app/profile/mcuban.bsky.social">followers </a>make him one of the most followed accounts. Cuban has 8.8 million <a href="https://x.com/mcuban/">followers </a>on X for comparison.
During a recent <a href="https://www.youtube.com/watch?v=oEK2063FPLw">interview </a>with Jules Terpak, Cuban discussed the current climate of social media and said that all the platforms are algorithmically driven except for one, naming Bluesky as the outlier.
"There's no algorithm," Cuban said.
Cuban highlighted several features of Bluesky during the interview including the limited number of bots, an "old school" chronological order and the ability to make your own lists with the open-source code.
When it comes to what sets Bluesky apart from X, Cuban highlighted one item as the "holy grail." "You truly own your threads."
Cuban said Bluesky users have complete control over the threads on their posts, including the quote replies. "There's a hide for everyone and there's a block that really works."
The entrepreneur said he saw a high volume of people come over from X to Bluesky to troll him during the 2024 election sharing memes and what he referenced as the "Rachel Maddow" pictures, which compare the TV host and investor's resemblance. Cuban said he could block people and hide the replies on posts from trolls for everyone.
Cuban says he sees a lower volume of trolls on Bluesky versus X, where he can't even engage with anyone anymore due to the trolls. The investor recently counted 246 replies on a post on Bluesky and only five were from trolls.
On Bluesky, Cuban is having engaging conversations with people and making fun posts for the first time in years on topics he enjoys talking with others about.
"People have lost the connection to just have normal engagement."
Cuban said his followers on Bluesky are far more engaging than on Twitter, referencing a Bluesky post that recently got 110,000 likes.
"The engagement is insane. You can have a social friendly, intellectual conversation on Bluesky."
You may not be a billionaire like Mark Cuban, but you can uncover hidden gems in the stock market using our proprietary data and pattern recognition — <a href="https://www.benzinga.com/general/social-media/24/12/42490690/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">check out five stocks flying under the radar that deserve your attention.</a>
TikTok Ban: During the interview, Cuban and Terpak also discussed the pending ban of TikTok in the U.S. unless the company's U.S. division is sold off.
Cuban said he loved the old TikTok and referenced being on the musical.ly platform, which went on to become TikTok, saying he tried to invest in that precursor company.
TikTok changed the world with quick videos, dance and attention grabbing content, but a push to make money made the platform feel more corporate, Cuban added.
To fight off a potential ban, TikTok brought in Cuban for a meeting to share suggestions on how to get around the troubles, he told Terpak. Cuban said he suggested to the company to have an output in the form of a url for the feed of videos watched by anyone 16 and under.
This would make it to where parents would be able to go back and see the list and watch videos their children had watched at any given time. Cuban said this would be good for parents and a governmental perspective to make sure there wasn't propaganda forced on people.
Cuban was asked what the biggest takeaway from TikTok is if the platform is banned.
"The biggest learning is he who controls the algorithm wins."
Cuban said TikTok was an early winner of using an algorithm to put content that people would like in front of them based on what they were watching and were liking.
While there is a potential ban date of Jan. 19 for TikTok in the U.S., which is the day before President Donald Trump's inauguration, Cuban is skeptical this will be the last day anyone sees TikTok videos.
"TikTok will sue and won't get closed on the 19th, that I'm confident of."
Cuban also referenced one of Trump's friends having a stake in the company, which is likely in reference to investor Jeff Yass, who is a Republican megadonor, <a href="https://www.benzinga.com/general/social-media/24/03/37722366/why-did-donald-trump-change-his-mind-about-tiktok-follow-the-money-says-rep-nancy-pelosi">owning a 15% stake</a> in TikTok parent ByteDance.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/24/09/40741507/mark-cuban-shares-advice-he-would-give-to-his-younger-self-i-wish-someone-told-me">Mark Cuban Shares Advice He Would Give To His Younger Self, &#8216;I Wish Someone Told Me…&#8217;</a></li>
</ul>

Mark Cuban Says This Is The 'Holy Grail' That Makes Bluesky Better Than Musk's X Platform

BJ's Wholesale Club (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BJ#NYSE">BJ</a>) has outperformed the market over the past 5 years by 20.47% on an annualized basis producing an average annual return of 33.25%. Currently, BJ's Wholesale Club has a market capitalization of $12.46 billion. 
Buying $1000 In BJ: If an investor had bought $1000 of BJ stock 5 years ago, it would be worth $4,239.10 today based on a price of $94.32 for BJ at the time of writing.
<h3>BJ's Wholesale Club's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734562814_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In BJ's Wholesale Club 5 Years Ago Would Be Worth This Much Today

AAOI

Applied Optoelectronics Plans Private Exchange Offer For 2026 Notes And Concurrent Registered Direct Offering

Domino's Pizza (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) has outperformed the market over the past 10 years by 5.31% on an annualized basis producing an average annual return of 16.24%. Currently, Domino's Pizza has a market capitalization of $14.87 billion. 
Buying $1000 In DPZ: If an investor had bought $1000 of DPZ stock 10 years ago, it would be worth $4,491.24 today based on a price of $430.71 for DPZ at the time of writing.
<h3>Domino's Pizza's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734561910_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Domino's Pizza 10 Years Ago Would Be Worth This Much Today

"We narrowed our full year adjusted earnings per share range and modestly lowered the midpoint given the slower than expected macroeconomic improvements and lower than expected orders in the first half of the year. Our updated guidance continues to reflect full year sales and EPS growth over fiscal 2024," the company said.

Guidance

MLKN

MillerKnoll Trims FY25 Adj EPS Outlook From Prior $2.20 To New Range Of $2.11 - $2.17, Est $2.16

United Airlines Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) has outperformed the market over the past 15 years by 2.2% on an annualized basis producing an average annual return of 13.84%. Currently, United Airlines Holdings has a market capitalization of $30.08 billion. 
Buying $100 In UAL: If an investor had bought $100 of UAL stock 15 years ago, it would be worth $698.78 today based on a price of $91.47 for UAL at the time of writing.
<h3>United Airlines Holdings's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734561014_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

BILL

BILL Holdings To Replace Lennox In S&P Midcap 400 Effective Prior To Opening Of Trading On December 23

CTLT

Lennox To Replace Catalent In S&P 500, Effective Prior To Opening Of Trading On Monday, December 23

Lennar Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) shares are sinking in Wednesday&#8217;s after-hours session after the company reported worse-than-expected financial results for the fourth quarter. Here&#8217;s a look at the <a href="https://www.benzinga.com/pressreleases/24/12/n42564471/lennar-reports-fourth-quarter-and-fiscal-2024-results">key metrics from the quarter</a>.
<ul>
<li>Q4 Revenue: $9.95 billion, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $10.08 billion</li>
</ul>
<ul>
<li>Q4 Adjusted EPS: $4.03, versus estimates of $4.16</li>
</ul>
Lennar said deliveries decreased 7% year-over-year to 22,206 homes. New orders in the period declined 3% to 16,895 homes, below the low end of the company&#8217;s previous guidance of 19,000 homes. The homebuilder had a backlog of 11,633 homes with an estimated value of $5.4 billion at quarter&#8217;s end.
Lennar reported homebuilding operating earnings of $1.5 billion, financial services operating earnings of $154 million and a multifamily operating loss of approximately $200,000. The company ended the quarter with homebuilding cash and cash equivalents of $4.7 billion, and total liquidity of approximately $7.6 billion.
&#8220;In the course of our&nbsp;fourth quarter, the housing market that appeared to be improving as the Fed cut short-term interest rates, proved to be far more challenging as mortgage rates rose almost 100 basis points through the quarter,&#8221; said Stuart Miller, executive chairman and co-CEO of Lennar.
&#8220;Even while demand remained strong, and the chronic supply shortage continued to drive the market, our results were driven by affordability limitations from higher interest rates.&#8221;
Lennar said it repurchased $521 million of its common stock during the quarter.
What&#8217;s Next: Lennar expects first-quarter deliveries of 17,000 to 17,500 homes. The company also guided for full-year 2025 deliveries of 86,000 to 88,000 homes. Lennar expects first-quarter gross margin to be between 19% and 19.25%, down from 22.1% in the fourth quarter.
&#8220;At this time, we will not guide to full-year gross margin until we have a better sense of market conditions as the year unfolds,&#8221; Miller said.
LEN Price Action: Lennar shares were down 7.49% after hours, trading at $135 at the time of publication Wednesday, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42488357/homebuilders-2025-outlook-more-cautious-less-constructive-analyst-says">Homebuilders 2025 Outlook: &#8216;More Cautious, Less Constructive,&#8217; Analyst Says</a></li>
</ul>
Photo: Shutterstock.

After-Hours Center

Movers

Real Estate

Lennar Stock Tumbles As Homebuilder Flags 'Far More Challenging' Housing Market Than Anticipated

Medical Properties Trust Reaches Agreement With Viceroy Research And Its Members To Mutually Settle And Dismiss Defamation Lawsuit Filed In 2023; Terms Confidential

Sterling Bancorp Receives Shareholder Approval For Sale Of Sterling Bank And Trust, F.S.B. To EverBank Financial And Approval Of Plan Of Dissolution

The Transaction, which reflects the completion of the previously announced strategic review of Sonoco's TFP business, is subject to customary closing conditions, including regulatory approvals, and is expected to close in the first half of 2025.&nbsp;
Net proceeds from the transaction are expected to be used to repay existing debt.
 &nbsp;

Asset Sales

Sonoco Products Enters Agreement To Sell Its Thermoformed And Flexibles Packaging Business To TOPPAN For $1.8B

In the last three months, 6 analysts have published ratings on Angi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGI#NASDAQ">ANGI</a>), offering a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $3.08, along with a high estimate of $6.00 and a low estimate of $2.00. This current average has decreased by 18.73% from the previous average price target of $3.79. 
<img src="https://www.benzinga.com/files/images/story/2024/1734559260_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Angi. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nicholas Jones</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$3.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Justin Patterson</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$2.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Eric Sheridan</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$2.50</td>
<td>$3.25</td>
</tr>
<tr>
<td>Daniel Kurnos</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$6.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Nicholas Jones</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$3.00</td>
<td>$3.25</td>
</tr>
<tr>
<td>Ygal Arounian</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$2.00</td>
<td>$3.25</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Angi. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Angi compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Angi's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ANGI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Angi analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Angi</h2>
Angi Inc connects quality home service professionals across different categories, from repairing and remodeling to cleaning and landscaping, with consumers. The Company has three operating segments namely, Ads and Leads that generate maximum revenue, Services, and International (Europe and Canada). The company operates under multiple brands that including Angi, HomeAdvisor, and Handy. The majority of the revenue is earned from the United States.
<h3>Breaking Down Angi's Financial Performance</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Angi's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -15.52%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Communication Services sector.
Net Margin: Angi's net margin is impressive, surpassing industry averages. With a net margin of 11.85%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Angi's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 3.33%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Angi's ROA excels beyond industry benchmarks, reaching 1.9%. This signifies efficient management of assets and strong financial health.
Debt Management: Angi's debt-to-equity ratio is below the industry average at 0.46, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANGI

6 Analysts Have This To Say About Angi

6 analysts have shared their evaluations of Albemarle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $120.33, a high estimate of $170.00, and a low estimate of $79.00. This upward trend is apparent, with the current average reflecting a 6.96% increase from the previous average price target of $112.50.
<img src="https://www.benzinga.com/files/images/story/2024/1734559251_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Albemarle. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ben Kallo</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$103.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$133.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Aleksey Yefremov</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$127.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Colin Rusch</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$170.00</td>
<td>$171.00</td>
</tr>
<tr>
<td>Ben Kallo</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$79.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$110.00</td>
<td>$100.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Albemarle. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Albemarle compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Albemarle's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Albemarle's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ALB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Albemarle analyst ratings.</a>
<h2>Get to Know Albemarle Better</h2>
Albemarle is one of the world's largest lithium producers. In the lithium industry, the majority of demand comes from batteries, where lithium is used as the energy storage material, particularly in electric vehicles. Albemarle is a fully integrated lithium producer. Its upstream resources include salt brine deposits in Chile and the US and two hard rock mines in Australia, both of which are joint ventures. The company operates lithium refining plants in Chile, the US, Australia, and China. Albemarle is a global leader in the production of bromine, used in flame retardants. It is also a major producer of oil refining catalysts.
<h3>Unraveling the Financial Story of Albemarle</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Albemarle's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -41.37%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Materials sector.
Net Margin: Albemarle's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -81.99%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Albemarle's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -13.07%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Albemarle's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -6.2%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Albemarle's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.45.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Albemarle In The Eyes Of 6 Experts

5 analysts have expressed a variety of opinions on 4D Molecular Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDMT#NASDAQ">FDMT</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $33.6, along with a high estimate of $46.00 and a low estimate of $8.00. Observing a downward trend, the current average is 30.72% lower than the prior average price target of $48.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1734559243_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of 4D Molecular Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$46.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>Judah Frommer</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Underweight</td>
<td>$8.00</td>
<td>-</td>
</tr>
<tr>
<td>Geulah Livshits</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$39.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Matthew Caufield</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$36.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$39.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to 4D Molecular Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of 4D Molecular Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of 4D Molecular Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of 4D Molecular Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/FDMT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on 4D Molecular Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About 4D Molecular Therapeutics</h2>
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
<h3>Understanding the Numbers: 4D Molecular Therapeutics's Finances</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, 4D Molecular Therapeutics faced challenges, resulting in a decline of approximately -99.99% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: 4D Molecular Therapeutics's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -1461433.33%, the company may face hurdles in effective cost management.
Return on Equity (ROE): 4D Molecular Therapeutics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -7.68%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): 4D Molecular Therapeutics's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -7.16% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.04.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FDMT

What 5 Analyst Ratings Have To Say About 4D Molecular Therapeutics

William Blair analyst Dylan Becker maintained a Buy rating on Enfusion (ENFN – Research Report) today. The company's shares opened today at $9.12. ...

William Blair Remains a Buy on Enfusion (ENFN)

Enfusion, Inc. (ENFN) Q3 2024 Earnings Call Transcript

Stifel Nicolaus analyst J. Parker Lane maintained a Buy rating on Enfusion (ENFN – Research Report) today and set a price target of $11.00. J. Park...

Enfusion: Strong Client Acquisitions and Strategic Positioning Drive Buy Rating

Stifel raised the firm's price target on Enfusion (ENFN) to $11 from $10 and keeps a Buy rating on the shares following third quarter results. New ...

Enfusion price target raised to $11 from $10 at Stifel

Enfusion, Inc. ( ($ENFN) ) has released its Q3 earnings. Here is a breakdown of the information Enfusion, Inc. presented to its investors. Enfusion...

Enfusion, Inc. Reports Strong Q3 2024 Results

Morgan Stanley analyst Michael Infante maintained a Buy rating on Enfusion (ENFN – Research Report) today and set a price target of $11.00. Michael...

Enfusion: A Strategic Opportunity with High Growth Potential and Attractive Valuation

Companies in the Technology sector have received a lot of coverage today as analysts weigh in on Block (SQ – Research Report), Silicon Laboratories...

Analysts Offer Insights on Technology Companies: Block (SQ), Silicon Laboratories (SLAB) and Enfusion (ENFN)

MoneyLion Has An Unusual M&A Deal For You

Stifel raised the firm's price target on Enfusion (ENFN) to $13 from $11 and keeps a Buy rating on the shares. After a bumpy start to 2024, the yea...

Enfusion price target raised to $13 from $11 at Stifel

Microsoft and more big software names look to grow in 2025 on AI monetization: Stifel

CYBR

DAVE

DDOG

DOCN

FTNT

MSFT

NRDS

SLAB

SOFI

TWLO

Press Releases

ZEMA Global Data Corporation to Acquire Morningstar Commodity Data

VALD Secures Significant Growth Equity Investment from FTV Capital

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Enfusion, Inc. - ENFN

Enfusion Announces Date of Third Quarter 2024 Results

FTV Capital and One Mind at Work Launch Partnership to Support Mental Health Within High-Growth Companies

Enfusion Announces Key Leadership Team Additions to Drive Client Success and Fuel Innovation

FTV Capital Named to Inc.'s Founder-Friendly Investors List for Fourth Consecutive Year

Enfusion Announces Third Quarter 2024 Results

Enfusion To Present at Upcoming Investor Events

Orbus Software Announces Strategic Growth Investment from FTV Capital and SilverTree Equity

GLOB

Amplitude

Blend Labs

Bit Digital

Daily Journal Corp. (S.C.) - Common Stock

Daily Journal

Digimarc

E2open Parent Holdings, Inc.Class A Common Stock

E2open Parent Holdings

Exodus Movement, Inc. Class A Common Stock

BitFuFu

AMTD Digital Inc. American Depositary Shares (every five of which represent two Class A Ordinary Shares)

AMTD Digital

Karooooo

Mitek Systems

MeridianLink

Matterport

Opera Limited - American Depositary Shares

Opera

PagerDuty

Pagaya Technologies Ltd. - Class A Ordinary Shares

Pagaya Techs

Porch Group

Pros Holdings

Red Violet

Riskified

Tuya Inc. American Depositary Shares, each representing one Class A Ordinary Share

Comments

Enfusion

Enfusion (ENFN) Options

Enfusion (NYSE:ENFN) Stock, Option Chain

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga